TW201326132A - 合成依伐布雷定(ivabradine)及其與醫藥上可接受酸之加成鹽之新穎方法 - Google Patents
合成依伐布雷定(ivabradine)及其與醫藥上可接受酸之加成鹽之新穎方法 Download PDFInfo
- Publication number
- TW201326132A TW201326132A TW101141192A TW101141192A TW201326132A TW 201326132 A TW201326132 A TW 201326132A TW 101141192 A TW101141192 A TW 101141192A TW 101141192 A TW101141192 A TW 101141192A TW 201326132 A TW201326132 A TW 201326132A
- Authority
- TW
- Taiwan
- Prior art keywords
- group
- optionally substituted
- heteroaromatic
- aromatic
- formula
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 21
- 229960003825 ivabradine Drugs 0.000 title claims abstract description 13
- ACRHBAYQBXXRTO-OAQYLSRUSA-N ivabradine Chemical compound C1CC2=CC(OC)=C(OC)C=C2CC(=O)N1CCCN(C)C[C@H]1CC2=C1C=C(OC)C(OC)=C2 ACRHBAYQBXXRTO-OAQYLSRUSA-N 0.000 title claims abstract 3
- 230000015572 biosynthetic process Effects 0.000 title abstract description 8
- 238000003786 synthesis reaction Methods 0.000 title abstract description 8
- 239000002253 acid Substances 0.000 title abstract description 6
- 150000003839 salts Chemical class 0.000 title abstract description 5
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 50
- 239000003054 catalyst Substances 0.000 claims description 36
- 150000001875 compounds Chemical class 0.000 claims description 34
- 125000001072 heteroaryl group Chemical group 0.000 claims description 30
- 238000006268 reductive amination reaction Methods 0.000 claims description 29
- 125000003118 aryl group Chemical group 0.000 claims description 27
- 229910052742 iron Inorganic materials 0.000 claims description 23
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 14
- 125000001931 aliphatic group Chemical group 0.000 claims description 14
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 13
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 12
- 150000001412 amines Chemical class 0.000 claims description 12
- 125000006575 electron-withdrawing group Chemical group 0.000 claims description 12
- 229910052739 hydrogen Inorganic materials 0.000 claims description 12
- 239000001257 hydrogen Substances 0.000 claims description 12
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims description 10
- 239000002904 solvent Substances 0.000 claims description 10
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 9
- 125000001960 7 membered carbocyclic group Chemical group 0.000 claims description 8
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 8
- 229910052799 carbon Inorganic materials 0.000 claims description 8
- 125000000623 heterocyclic group Chemical group 0.000 claims description 8
- -1 phosphite diester Chemical class 0.000 claims description 8
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 claims description 7
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 6
- UYPYRKYUKCHHIB-UHFFFAOYSA-N trimethylamine N-oxide Chemical compound C[N+](C)(C)[O-] UYPYRKYUKCHHIB-UHFFFAOYSA-N 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 5
- 125000003277 amino group Chemical group 0.000 claims description 4
- 125000001033 ether group Chemical group 0.000 claims description 4
- 229910052757 nitrogen Inorganic materials 0.000 claims description 4
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 4
- 239000003960 organic solvent Substances 0.000 claims description 4
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 4
- OJMIONKXNSYLSR-UHFFFAOYSA-N phosphorous acid Chemical compound OP(O)O OJMIONKXNSYLSR-UHFFFAOYSA-N 0.000 claims description 4
- 229910052717 sulfur Chemical group 0.000 claims description 4
- JZTPOMIFAFKKSK-UHFFFAOYSA-N O-phosphonohydroxylamine Chemical compound NOP(O)(O)=O JZTPOMIFAFKKSK-UHFFFAOYSA-N 0.000 claims description 3
- JHRWWRDRBPCWTF-OLQVQODUSA-N captafol Chemical compound C1C=CC[C@H]2C(=O)N(SC(Cl)(Cl)C(Cl)Cl)C(=O)[C@H]21 JHRWWRDRBPCWTF-OLQVQODUSA-N 0.000 claims description 3
- 150000002825 nitriles Chemical class 0.000 claims description 3
- 229910052698 phosphorus Inorganic materials 0.000 claims description 3
- 229910000073 phosphorus hydride Inorganic materials 0.000 claims description 3
- 125000003107 substituted aryl group Chemical group 0.000 claims description 3
- ADLVDYMTBOSDFE-UHFFFAOYSA-N 5-chloro-6-nitroisoindole-1,3-dione Chemical group C1=C(Cl)C([N+](=O)[O-])=CC2=C1C(=O)NC2=O ADLVDYMTBOSDFE-UHFFFAOYSA-N 0.000 claims description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 2
- 150000004982 aromatic amines Chemical class 0.000 claims description 2
- 150000008378 aryl ethers Chemical class 0.000 claims description 2
- 125000004429 atom Chemical group 0.000 claims description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 2
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 claims description 2
- 125000005843 halogen group Chemical group 0.000 claims description 2
- 150000002527 isonitriles Chemical class 0.000 claims description 2
- IBIRZFNPWYRWOG-UHFFFAOYSA-N phosphane;phosphoric acid Chemical compound P.OP(O)(O)=O IBIRZFNPWYRWOG-UHFFFAOYSA-N 0.000 claims description 2
- XRBCRPZXSCBRTK-UHFFFAOYSA-N phosphonous acid Chemical compound OPO XRBCRPZXSCBRTK-UHFFFAOYSA-N 0.000 claims description 2
- 125000004437 phosphorous atom Chemical group 0.000 claims description 2
- 239000011593 sulfur Substances 0.000 claims description 2
- 125000004434 sulfur atom Chemical group 0.000 claims description 2
- 230000002194 synthesizing effect Effects 0.000 claims description 2
- 238000001308 synthesis method Methods 0.000 claims 12
- 150000001721 carbon Chemical group 0.000 claims 3
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 claims 1
- 150000004677 hydrates Chemical class 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 22
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 15
- 238000002360 preparation method Methods 0.000 description 14
- HLUKNZUABFFNQS-ZMBIFBSDSA-N ivabradine hydrochloride Chemical compound Cl.C1CC2=CC(OC)=C(OC)C=C2CC(=O)N1CCCN(C)C[C@H]1CC2=C1C=C(OC)C(OC)=C2 HLUKNZUABFFNQS-ZMBIFBSDSA-N 0.000 description 11
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 8
- 150000001299 aldehydes Chemical class 0.000 description 8
- XKRFYHLGVUSROY-UHFFFAOYSA-N argon Substances [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 8
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Substances N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 8
- QNLOWBMKUIXCOW-UHFFFAOYSA-N indol-2-one Chemical compound C1=CC=CC2=NC(=O)C=C21 QNLOWBMKUIXCOW-UHFFFAOYSA-N 0.000 description 8
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 8
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 229910052786 argon Inorganic materials 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 4
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 4
- 229910052763 palladium Inorganic materials 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 150000004678 hydrides Chemical class 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 230000033764 rhythmic process Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- OBGFCRHZMSQCOL-UHFFFAOYSA-N 3-(7,8-dimethoxy-4-oxo-2,5-dihydro-1h-3-benzazepin-3-yl)propanal Chemical compound C1CN(CCC=O)C(=O)CC2=C1C=C(OC)C(OC)=C2 OBGFCRHZMSQCOL-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 150000004698 iron complex Chemical class 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 239000010970 precious metal Substances 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 229910001220 stainless steel Inorganic materials 0.000 description 2
- 239000010935 stainless steel Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- MHZGKXUYDGKKIU-UHFFFAOYSA-N Decylamine Chemical compound CCCCCCCCCCN MHZGKXUYDGKKIU-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical class [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 description 1
- RHQDFWAXVIIEBN-UHFFFAOYSA-N Trifluoroethanol Chemical compound OCC(F)(F)F RHQDFWAXVIIEBN-UHFFFAOYSA-N 0.000 description 1
- 239000003905 agrochemical Substances 0.000 description 1
- 150000001448 anilines Chemical class 0.000 description 1
- 239000012300 argon atmosphere Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 150000002466 imines Chemical class 0.000 description 1
- 229910052741 iridium Inorganic materials 0.000 description 1
- GKOZUEZYRPOHIO-UHFFFAOYSA-N iridium atom Chemical compound [Ir] GKOZUEZYRPOHIO-UHFFFAOYSA-N 0.000 description 1
- 150000002505 iron Chemical class 0.000 description 1
- 150000002506 iron compounds Chemical class 0.000 description 1
- 159000000014 iron salts Chemical class 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 229960000504 ivabradine hydrochloride Drugs 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 150000002736 metal compounds Chemical class 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- ZXDZVVSOWQEMOD-UHFFFAOYSA-N nitric hydrazide Chemical compound NN[N+]([O-])=O ZXDZVVSOWQEMOD-UHFFFAOYSA-N 0.000 description 1
- 229910000510 noble metal Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229910052762 osmium Inorganic materials 0.000 description 1
- SYQBFIAQOQZEGI-UHFFFAOYSA-N osmium atom Chemical compound [Os] SYQBFIAQOQZEGI-UHFFFAOYSA-N 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000004713 phosphodiesters Chemical class 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 229910052707 ruthenium Inorganic materials 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- KAKQVSNHTBLJCH-UHFFFAOYSA-N trifluoromethanesulfonimidic acid Chemical compound NS(=O)(=O)C(F)(F)F KAKQVSNHTBLJCH-UHFFFAOYSA-N 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
- B01J31/16—Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
- B01J31/22—Organic complexes
- B01J31/2282—Unsaturated compounds used as ligands
- B01J31/2295—Cyclic compounds, e.g. cyclopentadienyls
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J35/00—Catalysts, in general, characterised by their form or physical properties
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/16—Benzazepines; Hydrogenated benzazepines
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2235/00—Indexing scheme associated with group B01J35/00, related to the analysis techniques used to determine the catalysts form or properties
- B01J2235/05—Nuclear magnetic resonance [NMR]
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Cardiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Materials Engineering (AREA)
- Inorganic Chemistry (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Catalysts (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
本發明係關於合成式(I)之依伐布雷定(ivabradine):□其與醫藥上可接受酸之加成鹽及其水合物的方法。
Description
本發明係關於一種合成式(I)之依伐布雷定(ivabradine):
或3-{3-[{[(7S)-3,4-二甲氧基雙環[4.2.0]辛-1,3,5-三烯-7-基]甲基}(甲基)胺基]-丙基}-7,8-二甲氧基-1,3,4,5-四氫-2H-3-苯并氮呯-2-酮,其與醫藥上可接受酸之加成鹽及其水合物的方法。
依伐布雷定及其與醫藥上可接受酸之加成鹽(且更特別者為其鹽酸鹽)具有極高價值之藥理學及治療特性,尤其是心律減緩特性,致使彼等化合物適用於治療或預防各種心肌局部缺血脂臨床病狀(諸如心絞痛、心肌梗塞及相關心律紊亂),及與心律紊亂(尤其是室上性心律紊亂)及心臟衰竭有關之各種病態。
依伐布雷定及其與醫藥上可接受酸之加成鹽(且更特別者為其鹽酸鹽)之製備及治療用途已描述於歐洲專利說明書EP 0 534 859中。令人遺憾的是,彼專利說明書所述之依伐布雷定合成途徑會得到產率僅為1%之預期產物。
另一種以還原胺化反應為基礎之依伐布雷定合成途徑已描述於歐洲專利說明書EP 1 589 005中。
還原胺化是一種用以製備胺之有利方法的途徑。因為此方法不需要分離所形成之中間亞胺,所以在還原劑存在下醛與胺之間發生的此偶合反應可廣泛地用於合成在醫藥或農用化學領域及材料科學中有價值的化合物。
常規用於進行還原胺化之程序性方案為:‧使用化學計量之量的氫化物供體,例如硼氫化物(NaBH4、NaBH3CN或NaBH(OAc)3),‧或催化性氫化作用。
使用氫化物供體會產生許多廢物,且該等試劑本身有毒。
在催化性氫化作用之情況下,還原劑為分子氫之實情必然具有環境價值。專利說明書EP 1 589 005中所述之合成是遵循此第二途徑。
亦即,專利說明書EP 1 589 005係描述以式(II)化合物為起始物來合成依伐布雷定鹽酸鹽:
該式(II)化合物在氫及鈀催化劑存在下進行催化性氫化作用反應,得到式(III)化合物:
該式(III)化合物未經分離,即在氫及鈀催化劑存在下與式
(IV)化合物反應:
得到呈鹽酸鹽形式之式(I)依伐布雷定。
彼合成途徑之缺點是使用鈀催化劑。
類似於同樣用於催化還原胺化反應之金屬銠、釕或銥,鈀為貴金屬,其稀缺性及由此所致之高價以及毒性限制了其可接受性。
本申請案描述一種依伐布雷定合成途徑,其可免除使用貴金屬。
亦即,本發明係關於一種合成式(I)之依伐布雷定的方法:
其特徵在於式(V)化合物:
與式(VI)之胺:
在鐵基催化劑存在下,在存在或不存在三甲胺N-氧化物之情況下,在氫氣壓力下,在有機溶劑或有機溶劑之混合物中,進行還原胺化反應。
不同於貴金屬化合物,鐵化合物通常無毒且鐵鹽大量存在於自然界中,該等為對環境無害之金屬實體。本發明建議使用另外易於處理之金屬錯合物。
已知鐵錯合物在矽烷化氫化物存在下可催化還原胺化反應(Enthaler S.ChemCatChem 2010,2,1411-1415),但在描述以催化性氫化作用為基礎之還原胺化的文獻方面僅有兩個實例(Bhanage B.M.等人Tet.Lett. 2008,49,965-969;Beller M.等人Chem Asian J. 2011,6,2240-2245)。
由Bhanage描述之操作條件需要在加熱至高溫之介質中及在高氫壓下存在由鐵(II)鹽及EDTA構成之水溶性錯合物。
應用彼公開案中所述之操作條件來製備依伐布雷定並無法獲得預期產物。
下表概述在30巴(bar)氫氣下在4 mL脫氣水存在下於20 mL高壓釜中進行18小時之測試。反應在0.5 mmol規模下以1/1.5之醛/胺比(除第1行:醛/胺(1/1)且添加1%對甲苯磺酸)進行。量(mol%)以醛計。
NTf為三氟甲烷磺醯胺之縮寫。
Beller之公開案描述在65℃下於50巴氫氣下在甲苯中於Fe3(CO)12存在下多種醛由苯胺衍生物進行還原胺化。
應用彼公開案中所述之操作條件來製備依伐布雷定無法獲得預期產物。
下表概述在25巴氫氣下於65℃下在多種溶劑中於1.7 mol% Fe3(CO)12存在下進行18小時之測試。
反應在4 mL脫氣溶劑存在下於20 mL高壓釜中進行。
測試在1 mmol規模下以1/1之醛/胺比與1%對甲苯磺酸進行。
式(V)化合物與式(VI)化合物之還原胺化反應中所用之鐵基催化劑較佳具有以下通式:
其中R1、R2、R3及R4獨立地表示:‧氫原子,或‧基團-SiR5R6R7,其中R5、R6及R7獨立地表示視情況經取代之直鏈或分支鏈(C1-C6)烷基或視情況經取代之芳族或雜芳族基團,或‧視情況經取代之芳族或雜芳族基團,或‧視情況經取代之直鏈或分支鏈(C1-C6)烷基,或‧吸電子基團,或‧脂族、芳族、雜芳族或帶有吸電子基團之胺基,或‧脂族、芳族或雜芳族醚基,或成對R1與R2或R2與R3或R3與R4與帶有其之碳原子一起形成3員至7員碳環或雜環,X表示:‧氧原子,或‧-NH基團或經脂族、芳族、雜芳族或吸電子基團取代之氮原子,或‧-PH基團或經一或多個脂族、芳族或吸電子基團取代之磷原子,較佳形成膦、亞磷酸酯、亞膦酸二酯、胺基磷酸酯、亞膦酸酯、磷或磷琳基團,或‧硫原子,
L1、L2及L3獨立地表示羰基、腈、異腈、雜芳族、膦、亞磷酸酯、亞膦酸二酯、胺基磷酸酯、亞膦酸酯、磷、磷琳、脂族胺、芳族胺、雜芳族胺、帶有吸電子基團之胺、脂族醚、芳族醚、雜芳族醚、碸、亞碸或磺醯亞胺(sulphoximine)基團,或具有以下兩式之一的N-雜環碳烯基團:
其中Y及Z獨立地表示硫或氧原子或基團NR8,其中R8表示視情況經取代之烷基或視情況經取代之芳族或雜芳族基團,
K表示碳或氮原子,R9及R10獨立地表示氫原子,視情況經取代之烷基,視情況經取代之芳族或雜芳族基團,鹵素原子,脂族、芳族或雜芳族醚基,脂族、芳族或雜芳族胺基,或成對R9與R10與帶有其之原子一起形成3員至7員碳環或雜環;或
其中R11及R12獨立地表示視情況經取代之烷基或視情況經取代之芳族或雜芳族基團,且n為1或2。
吸電子基團為吸引電子能力超過分子中佔據相同位置之氫原子的基團。
在吸電子基團中,可提及以下基團:酯、酸、腈、醛、酮、醯胺、硝基、碸、亞碸、磺醯亞胺、磺醯胺或磷酸二酯,而不意味任何限制。
在本發明之一個實施例中,式(V)化合物與式(VI)化合物之還原胺化反應中所用之鐵基催化劑具有以下通式:
其中R2及R3各自表示氫原子,或與帶有其之碳原子一起形成3員至7員碳環或雜環,且R1及R4獨立地表示:‧基團-SiR5R6R7,其中R5、R6及R7獨立地表示視情況經取代之直鏈或分支鏈(C1-C6)烷基或視情況經取代之芳基,‧或視情況經取代之芳族或雜芳族基團,‧或視情況經取代之直鏈或分支鏈(C1-C6)烷基。
式(V)化合物與式(VI)化合物之還原胺化反應中所用之式(VIII)催化劑較佳係選自以下催化劑:
在本發明之另一實施例中,式(V)化合物與式(VI)化合物之還原胺化反應中所用之鐵基催化劑具有以下通式:
其中R2及R3各自表示氫原子,或與帶有其之碳原子一起形成3員至7員碳環或雜環,且R1及R4獨立地表示:‧基團-SiR5R6R7,其中R5、R6及R7獨立地表示視情況經取代之直鏈或分支鏈(C1-C6)烷基或視情況經取代之芳族或雜芳族基團,‧或視情況經取代之芳族或雜芳族基團,‧或視情況經取代之直鏈或分支鏈(C1-C6)烷基。
式(V)化合物與式(VI)化合物之還原胺化反應中所用之式(XIII)催化劑較佳係選自以下催化劑:
在本發明之另一實施例中,式(V)化合物與式(VI)化合物之還原胺化反應中所用之鐵基催化劑具有下式:
在本發明之另一實施例中,式(V)化合物與式(VI)化合物之還原胺化反應中所用之鐵基催化劑具有下式:
式(V)化合物與式(VI)化合物之還原胺化反應所用之催化劑含量以相對於醛計為1 mol%至10 mol%。
式(V)化合物與式(VI)化合物之還原胺化反應所用之三甲胺N-氧化物含量以相對於催化劑計為0至3當量,更佳以相對於催化劑計為0.5至1.5當量。
式(V)化合物與式(VI)化合物之還原胺化反應中的氫氣壓力較佳為1至20巴,更佳為1至10巴,且甚至更佳為1至5
巴。
在可用於進行式(V)化合物與式(VI)化合物之還原胺化反應的溶劑中,可以為醇(較佳為乙醇、異丙醇、三氟乙醇、第三丁醇或甲醇)、四氫呋喃、乙酸乙酯、乙腈及二噁烷,沒有任何限制。
較佳用於進行式(V)化合物與式(VI)化合物之還原胺化反應的溶劑為乙醇。
式(V)化合物與式(VI)化合物之間的還原胺化反應之溫度較佳為25℃至100℃,更佳為50℃至100℃,且甚至更佳為80℃至100℃。
下文中之實例說明本發明。
在70-230目矽膠上進行管柱層析純化程序。
在400 MHz下記錄1H NMR光譜。
化學位移以ppm表示(內標:TMS)。
已使用以下縮寫來描述峰:單峰(s)、二重峰(d)、雙二重峰(dd)、三重峰(t)、四重峰(q)、多重峰(m)。
本發明方法所用之催化劑可根據以下公開案中所述之方法來製備:Synlett 1992,第1002-1004頁;Synlett 1993,第924-926頁;及Advanced Synthesis and Catalysis 2012,354(4),第597-601頁。
在氬氣氛圍下,將1 mmol[(7S)-3,4-二甲氧基雙環[4.2.0]辛-1,3,5-三烯-7-基]-N-甲基甲胺及1 mmol 3-(7,8-二甲氧基-2-側氧基-1,2,4,5-四氫-3H-3-苯并氮呯-3-基)丙醛引入至潔淨且乾燥之不鏽鋼高壓釜中。藉由三次真空/氬氣循環將混合物進行脫氣,並添加2 mL經蒸餾及脫氣之乙醇。在85℃下攪拌該溶液1小時。
在氬氣氛圍下,於舒侖克管(Schlenk tube)中歷經30分鐘製備於1 mL乙醇中之5 mol%鐵錯合物與5 mol%三甲胺N-氧化物之混合物,隨後將其引入至高壓釜中。
隨後將高壓釜置於氫壓(5巴)下,且在85℃下攪拌反應混合物16小時,隨後將高壓釜返回至周圍溫度,且使其減壓。
使用乙酸乙酯作為溶劑經去活化中性氧化鋁(3%水)過濾該反應混合物。
在矽膠上(溶離劑:戊烷/乙酸乙酯(95/5),含0.5%三乙胺)純化粗產物,以獲得預期產物。
在氬氣氛圍下,將1 mmol[(7S)-3,4-二甲氧基雙環[4.2.0]辛-1,3,5-三烯-7-基]-N-甲基甲胺及1 mmol 3-(7,8-二甲氧基-2-側氧基-1,2,4,5-四氫-3H-3-苯并氮呯-3-基)丙醛引入至潔淨且乾燥之不鏽鋼高壓釜中。藉由三次真空/氬氣循環將混合物進行脫氣,且添加3 mL經蒸餾及脫氣之乙
醇。在85℃下攪拌該溶液1小時。在氬氣下添加鐵錯合物(5 mol%)。隨後將高壓釜置於氫壓(5巴)下,且在85℃下攪拌反應混合物16小時,隨後將高壓釜返回至周圍溫度且使其減壓。
使用乙酸乙酯作為溶劑經去活化中性氧化鋁(3%水)過濾該反應混合物。
在矽膠上(溶離劑:戊烷/乙酸乙酯(95/5),含0.5%三乙胺)純化粗產物,以獲得預期產物。
在式(IX)之鐵催化劑存在下,根據通用程序A製備3-{3-[{[(7S)-3,4-二甲氧基雙環[4.2.0]辛-1,3,5-三烯-7-基]甲基}(甲基)胺基]-丙基}-7,8-二甲氧基-1,3,4,5-四氫-2H-3-苯并氮呯-2-酮。
產率=61%
1H NMR(CDCl3):δ=6.67及6.64(2s,2H);6.55及6.50(2s,2H);3.79及3.78(2s,12H);3.76(s,2H);3.67(m,2H);3.45(m,3H);3.17(dd,1H);2.99(m,2H);2.65(m,2H);2.50(dd,1H);2.37(t,2H);2.26(s,3H);1.72(q,2H)。
在式(X)之鐵催化劑存在下,根據通用程序A製備3-{3-[{[(7S)-3,4-二甲氧基雙環[4.2.0]辛-1,3,5-三烯-7-基]甲基}(甲基)胺基]-丙基}-7,8-二甲氧基-1,3,4,5-四氫-2H-3-苯并氮呯-2-酮。
產率=63%
在式(XI)之鐵催化劑存在下,根據通用程序A製備3-{3-[{[(7S)-3,4-二甲氧基雙環[4.2.0]辛-1,3,5-三烯-7-基]甲基}(甲基)胺基]-丙基}-7,8-二甲氧基-1,3,4,5-四氫-2H-3-苯并氮呯-2-酮。
產率=79%
在式(XII)之鐵催化劑存在下,根據通用程序A製備3-{3-[{[(7S)-3,4-二甲氧基雙環[4.2.0]辛-1,3,5-三烯-7-基]甲基}(甲基)胺基]-丙基}-7,8-二甲氧基-1,3,4,5-四氫-2H-3-苯并氮呯-2-酮。
產率=68%
在式(XIV)之鐵催化劑存在下,根據通用程序B製備3-{3-[{[(7S)-3,4-二甲氧基雙環[4.2.0]辛-1,3,5-三烯-7-基]甲基}(甲基)胺基]-丙基}-7,8-二甲氧基-1,3,4,5-四氫-2H-3-苯并氮呯-2-酮。
產率=68%
在式(XV)之鐵催化劑存在下,根據通用程序B製備3-{3-[{[(7S)-3,4-二甲氧基雙環[4.2.0]辛-1,3,5-三烯-7-基]甲基}(甲基)胺基]-丙基}-7,8-二甲氧基-1,3,4,5-四氫-2H-3-苯并氮呯-2-酮。
產率=68%
在式(XVI)之鐵催化劑存在下,根據通用程序B製備3-{3-[{[(7S)-3,4-二甲氧基雙環[4.2.0]辛-1,3,5-三烯-7-基]甲基}(甲基)胺基]-丙基}-7,8-二甲氧基-1,3,4,5-四氫-2H-3-苯并氮呯-2-酮。
產率=59%
在式(XVII)之鐵催化劑存在下,根據通用程序B製備3-{3-[{[(7S)-3,4-二甲氧基雙環[4.2.0]辛-1,3,5-三烯-7-基]甲基}(甲基)胺基]-丙基}-7,8-二甲氧基-1,3,4,5-四氫-2H-3-苯并氮呯-2-酮。
產率=48%
Claims (15)
- 一種合成式(I)之依伐布雷定(ivabradine)之方法,
- 如請求項1之合成方法,其中該鐵基催化劑具有以下通式:
- 如請求項2之合成方法,其中該鐵基催化劑具有以下通式:
- 如請求項3之合成方法,其中該鐵基催化劑係選自:
- 如請求項2之合成方法,其中該鐵基催化劑具有以下通式:
- 如請求項5之合成方法,其中該鐵基催化劑係選自:
- 如請求項2之方法,其中該鐵基催化劑具有下式:
- 如請求項2之方法,其中該鐵基催化劑具有下式:
- 如請求項1至8中任一項之合成方法,其中該還原胺化反應所用之催化劑含量以相對於醛計為1 mol%至10 mol%。
- 如請求項1至8中任一項之合成方法,其中該還原胺化反應所用之三甲胺N-氧化物含量以相對於該催化劑計為0當量至3當量。
- 如請求項10之合成方法,其中該還原胺化反應所用之三甲胺N-氧化物含量以相對於該催化劑計為0.5當量至1.5當量。
- 如請求項1至8中任一項之合成方法,其中該還原胺化反應中之氫氣壓力為1巴至10巴。
- 如請求項1至8中任一項之合成方法,其中該還原胺化反應中之溶劑為醇。
- 如請求項13之合成方法,其中該還原胺化反應中之溶劑為乙醇。
- 如請求項1至8中任一項之合成方法,其中該還原胺化反應之溫度為50℃至100℃。
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR1103933A FR2984319B1 (fr) | 2011-12-20 | 2011-12-20 | Nouveau procede de synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable |
Publications (2)
Publication Number | Publication Date |
---|---|
TW201326132A true TW201326132A (zh) | 2013-07-01 |
TWI440627B TWI440627B (zh) | 2014-06-11 |
Family
ID=47115640
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW101141192A TWI440627B (zh) | 2011-12-20 | 2012-11-06 | 合成依伐布雷定(ivabradine)及其與醫藥上可接受酸之加成鹽之新穎方法 |
Country Status (35)
Country | Link |
---|---|
US (1) | US8513410B2 (zh) |
EP (1) | EP2607353B1 (zh) |
JP (1) | JP5670406B2 (zh) |
KR (1) | KR101470879B1 (zh) |
CN (1) | CN103172566B (zh) |
AR (1) | AR088678A1 (zh) |
AU (1) | AU2012244188B2 (zh) |
BR (1) | BR102012028614A2 (zh) |
CA (1) | CA2795741C (zh) |
CL (1) | CL2012003136A1 (zh) |
CY (1) | CY1115682T1 (zh) |
DK (1) | DK2607353T3 (zh) |
EA (1) | EA026510B1 (zh) |
ES (1) | ES2525032T3 (zh) |
FR (1) | FR2984319B1 (zh) |
GE (1) | GEP20156350B (zh) |
HK (1) | HK1186733A1 (zh) |
HR (1) | HRP20141023T1 (zh) |
JO (1) | JO3031B1 (zh) |
MA (1) | MA34276B1 (zh) |
MD (1) | MD4336C1 (zh) |
MX (1) | MX2012012938A (zh) |
MY (1) | MY170662A (zh) |
PE (1) | PE20131097A1 (zh) |
PL (1) | PL2607353T3 (zh) |
PT (1) | PT2607353E (zh) |
RS (1) | RS53541B1 (zh) |
SA (1) | SA112330994B1 (zh) |
SG (1) | SG191471A1 (zh) |
SI (1) | SI2607353T1 (zh) |
TW (1) | TWI440627B (zh) |
UA (1) | UA111329C2 (zh) |
UY (1) | UY34423A (zh) |
WO (1) | WO2013093220A1 (zh) |
ZA (1) | ZA201208160B (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2988720B1 (fr) * | 2012-03-27 | 2014-03-14 | Servier Lab | Nouveau procede de synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable |
CN105669554A (zh) * | 2016-02-22 | 2016-06-15 | 徐建立 | 一种盐酸伊伐布雷定杂质及其制备方法和应用 |
FR3071833B1 (fr) * | 2017-09-29 | 2020-01-03 | Universite Paris-Sud | Nouveau procede de synthese d'amines tertiaires dissymetriques |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2681862B1 (fr) * | 1991-09-27 | 1993-11-12 | Adir Cie | Nouvelles (benzocycloalkyl)alkylamines, leur procede de preparation, et les compositions pharmaceutiques qui les contiennent. |
US6225487B1 (en) * | 1998-04-17 | 2001-05-01 | Symyx Technologies, Inc. | Ancillary ligands and metal complexes, catalysts and compositions using same and methods of testing |
US6521793B1 (en) * | 1998-10-08 | 2003-02-18 | Symyx Technologies, Inc. | Catalyst ligands, catalytic metal complexes and processes using same |
FR2868777B1 (fr) * | 2004-04-13 | 2006-05-26 | Servier Lab | Nouveau procede de synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable |
EP1595888A1 (en) * | 2004-05-11 | 2005-11-16 | Degussa AG | Cycloolefin phosphine ligands and their use in catalysis |
WO2008065681A2 (en) * | 2006-11-30 | 2008-06-05 | Cadila Healthcare Limited | Process for preparation of ivabradine hydrochloride |
US7857994B2 (en) | 2007-05-30 | 2010-12-28 | GE Lighting Solutions, LLC | Green emitting phosphors and blends thereof |
ES2528026T3 (es) * | 2007-05-30 | 2015-02-03 | Ind-Swift Laboratories Limited | Sales de oxalato de ivabridina cristalino y polimorfos de los mismos |
FR2920773B1 (fr) * | 2007-09-11 | 2009-10-23 | Servier Lab | Derives de 1,2,4,5-tetrahydro-3h-benzazepines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
FR2933975B1 (fr) * | 2008-07-17 | 2011-02-18 | Servier Lab | Nouveau procede de preparation de benzocyclobutenes fonctionnalises,et application a la synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable. |
FR2935381B1 (fr) * | 2008-08-29 | 2010-12-17 | Servier Lab | Nouveau procede de resolution des enantiomerees du (3,4-dimethoxy-bicyclo°4.2.0!octa-1,3,5-trien-7-yl)nitrile et application a la synthese de l'ivabradine |
FR2940287B1 (fr) * | 2008-12-24 | 2010-12-24 | Servier Lab | Nouveau procede de synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable. |
FR2941695B1 (fr) * | 2009-02-04 | 2011-02-18 | Servier Lab | Nouveau procede de synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable |
-
2011
- 2011-12-20 FR FR1103933A patent/FR2984319B1/fr not_active Expired - Fee Related
-
2012
- 2012-10-23 JO JOP/2012/0320A patent/JO3031B1/ar active
- 2012-10-23 SG SG2012078705A patent/SG191471A1/en unknown
- 2012-10-24 CA CA2795741A patent/CA2795741C/fr not_active Expired - Fee Related
- 2012-10-24 AU AU2012244188A patent/AU2012244188B2/en not_active Ceased
- 2012-10-25 PE PE2012002077A patent/PE20131097A1/es active IP Right Grant
- 2012-10-30 MY MYPI2012700844A patent/MY170662A/en unknown
- 2012-10-30 ZA ZA2012/08160A patent/ZA201208160B/en unknown
- 2012-10-30 UY UY0001034423A patent/UY34423A/es not_active Application Discontinuation
- 2012-10-31 MD MDA20120094A patent/MD4336C1/ro not_active IP Right Cessation
- 2012-11-06 TW TW101141192A patent/TWI440627B/zh not_active IP Right Cessation
- 2012-11-07 MX MX2012012938A patent/MX2012012938A/es active IP Right Grant
- 2012-11-07 MA MA35353A patent/MA34276B1/fr unknown
- 2012-11-07 AR ARP120104179A patent/AR088678A1/es unknown
- 2012-11-08 UA UAA201212746A patent/UA111329C2/uk unknown
- 2012-11-08 KR KR1020120126314A patent/KR101470879B1/ko not_active Expired - Fee Related
- 2012-11-08 BR BR102012028614-9A patent/BR102012028614A2/pt not_active IP Right Cessation
- 2012-11-08 GE GEAP201212889A patent/GEP20156350B/en unknown
- 2012-11-08 CN CN201210443036.8A patent/CN103172566B/zh not_active Expired - Fee Related
- 2012-11-08 CL CL2012003136A patent/CL2012003136A1/es unknown
- 2012-11-09 PL PL12191902T patent/PL2607353T3/pl unknown
- 2012-11-09 DK DK12191902.1T patent/DK2607353T3/en active
- 2012-11-09 US US13/673,145 patent/US8513410B2/en not_active Expired - Fee Related
- 2012-11-09 WO PCT/FR2012/000451 patent/WO2013093220A1/fr active Application Filing
- 2012-11-09 EP EP12191902.1A patent/EP2607353B1/fr active Active
- 2012-11-09 JP JP2012247143A patent/JP5670406B2/ja active Active
- 2012-11-09 EA EA201201385A patent/EA026510B1/ru not_active IP Right Cessation
- 2012-11-09 PT PT121919021T patent/PT2607353E/pt unknown
- 2012-11-09 SI SI201230089T patent/SI2607353T1/sl unknown
- 2012-11-09 ES ES12191902.1T patent/ES2525032T3/es active Active
- 2012-11-09 RS RSP20140509 patent/RS53541B1/en unknown
- 2012-11-10 SA SA112330994A patent/SA112330994B1/ar unknown
-
2013
- 2013-12-23 HK HK13114205.7A patent/HK1186733A1/zh not_active IP Right Cessation
-
2014
- 2014-10-14 CY CY20141100832T patent/CY1115682T1/el unknown
- 2014-10-23 HR HRP20141023AT patent/HRP20141023T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2710632B2 (ja) | 光学活性な第二アミンの製造方法 | |
KR20080011320A (ko) | 시나칼셋 염기의 제조 방법 | |
TWI440627B (zh) | 合成依伐布雷定(ivabradine)及其與醫藥上可接受酸之加成鹽之新穎方法 | |
KR101243408B1 (ko) | 루테늄 화합물 및 광학 활성 아미노알코올 화합물의 제조 방법 | |
JP2021516657A (ja) | 四座pnnp配位子ルテニウム錯体でのカルボニルの水素化 | |
TWI440628B (zh) | 依伐布雷定(ivabradine)及其與醫藥上可接受酸之加成鹽的新合成方法 | |
NZ603483B (en) | New process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid | |
WO2008134326A1 (en) | Novel aldehyde composition | |
NZ604890B (en) | New process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Annulment or lapse of patent due to non-payment of fees |